DE NOVO PHARMACEUTICALS
De Novo Pharmaceuticals is an emerging computational drug design company. De Novo Pharmaceuticals uses its proprietary computational software for drug design to create novel, patentable lead molecules as candidates for drug development. De Novo's proprietary algorithms can convert information from structural genomics and medicinal chemistry rapidly into new chemical designs, maximising value within a pharmaceutical partner's research portfolio. De Novo's drug discovery partners include British Biotechnology, Aventis Pharmaceuticals and NV Organon.
DE NOVO PHARMACEUTICALS
Industry:
Health Care Life Science Medical Pharmaceutical
Founded:
1999-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Total Employee:
11+
Status:
Active
Contact:
+44 (0)1223 488888
Email Addresses:
[email protected]
Total Funding:
18.75 M GBP
Similar Organizations
Bard Pharmaceuticals
Bard Pharmaceuticals is a healthcare products manufacturing company.
Elpen Pharmaceutical
Elpen Pharmaceutical is a pharmaceutical company.
Pace Analytical Services
Pace Analytical is a leader in integrated drug development.
Tagworks Pharmaceuticals
Tagworks Pharmaceuticals is a privately held biotech company
Investors List
Roche Venture Fund
Roche Venture Fund investment in Series B - De Novo Pharmaceuticals
Quester
Quester investment in Series B - De Novo Pharmaceuticals
The Cambridge Gateway Fund
The Cambridge Gateway Fund investment in Series B - De Novo Pharmaceuticals
FNI Venture Capital
FNI Venture Capital investment in Series B - De Novo Pharmaceuticals
MVM Life Science Partners
MVM Life Science Partners investment in Series B - De Novo Pharmaceuticals
Merlin Biomed
Merlin Biomed investment in Series B - De Novo Pharmaceuticals
Avlar BioVentures
Avlar BioVentures investment in Series B - De Novo Pharmaceuticals
Incyte
Incyte investment in Series B - De Novo Pharmaceuticals
Prelude Trust
Prelude Trust investment in Series B - De Novo Pharmaceuticals
Prelude Trust
Prelude Trust investment in Series A - De Novo Pharmaceuticals